A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Latest Information Update: 03 Mar 2022
Price :
$35 *
At a glance
- Drugs Parsaclisib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-202
- Sponsors Incyte Corporation
- 05 Apr 2021 Status changed from active, no longer recruiting to completed.
- 01 Apr 2021 This trial has been completed in France (Global End Date: 05 Feb 2021), according to European Clinical Trials Database record.
- 26 Mar 2021 This trial has been completed in Belgium according to European Clinical Trials Database record.